XENIOS AG Sold to Fresenius Medical Care

KGaA (Bad Homburg vor der Höhe, Germany).

XENIOS AG focuses on the treatment of lung and cardiac failure, and provides systems for minimally invasive lung and cardiac assistance during serious illnesses and operations. Fresenius Medical Care provides products and services for individuals with renal diseases, including dialysis products such as dialysis machines or dialyzers. It has a network of 3,579 dialysis clinics, which provide dialysis treatments for 306,366 patients around the world. By entering the treatment of heart and lung diseases (cardiac and pulmonary diseases), Fresenius Medical Care intends to expand its position in the area of extracorporeal organ support.

"The long-term strategy of Zukunftsfonds Heilbronn continues to unfold. With Fresenius Medical Care AG, we have succeeded in bringing a true world market leader from the high-growth healthcare sector to Heilbronn,” said Thomas R. Villinger, CEO of zfhn. "Our top objective is to use the activities of zfhn to make Heilbronn a hub for many regional technology-focused companies. The takeover of XENIOS AG by Fresenius Medical Care AG will ensure a strong appeal for our region internationally and entice other innovative companies from the medical technology segment to look at our region.”

"Thanks to the longtime, professional support and guidance of zfhn in growing XENIOS AG, we are now able to take the next major step. Under the umbrella of Fresenius Medical Care AG, we will be able to continue our international growth course, particularly in North America and China, and open up new markets with innovative products. We are confident that our know-how in the field of cardiovascular system support will be a significant enrichment for the portfolio of Fresenius Medical Care AG. Having the support of a major partner gives us the ability to accelerate our growth course,” explained Dr. Georg Matheis, chairman and founder of XENIOS AG.

Dominik Wehner, the Management Board member who oversees the regions of Europe, the Middle East and Africa at Fresenius Medical Care, said, “We are acquiring an attractive company that makes a very reasonable addition to our product range. We are looking forward to working with our new colleagues. We will jointly focus on further growing the business on the basis of our strong position and on tapping into new markets.”

Dr. Olaf Schermeier, the Management Board member who directs research and development at Fresenius Medical Care, added, “Treating heart and lung diseases with extracorporeal therapy systems is closely tied to dialysis both in technological terms and in the clinical process. By combining XENIOS AG’s innovative products and the experience of Fresenius Medical Care, especially in the acute area, we can put these therapies into use on a broad-scale basis and achieve further progress that will benefit patients.”

Related Links:
XENIOS AG
Fresenius Medical Care